Skip to main content
Hit enter to search or ESC to close
A phase IIB, double-blind, randomised, active-controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fully vaccinated against covid-19 followed by an extension period to study a fourth dose administration of PHH-1V
© 2024 VHIR Annual Report 2022.
Data protection policy
Facts & Figures
Partners and Acknowledgements
VHIR Annual Report 2022